| Aug 6 |
SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas
|
| Jul 31 |
SELLAS Life Sciences announces $21M registered direct offering
|
| Jul 31 |
SELLAS Life Sciences Announces $21.0 Million Registered Direct Offering Priced at a Premium to Market
|
| Jul 16 |
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia
|
| Jul 8 |
SELLAS' SLS009 granted orphan drug designation by EMA for acute myeloid leukemia treatment
|
| Jul 8 |
SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia
|
| Jun 24 |
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia
|
| Jun 17 |
Sellas falls 17% amid Phase 3 study update for galinpepimut-S
|
| Jun 17 |
SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia
|
| Jun 10 |
SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML
|
